This report describes nucleotide sequence analysis of part of the polymerase gene of hepatitis B virus (HBV) during the development of lamivudine-resistant HBV in five patients who received lamivudine treatment in conjunction with liver transplantation. Samples from patients were analysed before, during and after drug treatment in conjunction with serum HBV quantification by PCR. Lamivudine resistance was found to be associated with L526M and M550V changes in two patients and M550I change in three patients. Other changes associated with lamivudine resistance in some patients were V509I, A546V, S565A and A568T. The effects on HBV surface antigen are also described. Some patients were subsequently treated with famciclovir and/or ganciclovir with variable outcomes. In two out of three patients who stopped lamivudine treatment, reversion (partial or complete) to wild-type virus was observed after about 5 months. In contrast, a complex mixture of mutant viruses emerged in a third patient who stopped lamivudine treatment.
References
1.
LaiC-L, ChienR-N, LeungN.W.Y., ChangT.T., GuanR., TaiD-I, NgK-y, WuP-C, DentJ.C., BarberJ., StephensonS.L., & GrayD.F.A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine1998; 339: 61–68.
2.
HonkoopP., NiestersH.G., deManR-A, OsterhausA.D., & SchalmS.W.Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. Journal of Hepatology1997; 26: 1393–1395.
3.
BartholomewM.M., JansenR.W., JeffersL.J., ReddyK.R., JohnsonL.C., BunzendahlH., CondreayL.D., TzakisA.G., SchiffE.R., & BrownN.A.Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet1997; 349: 20–22.
4.
ButiM., JardiR., CotrinaM., Rodriguez-FriasF., EstebanR., & GuardiaJ.Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. Journal of Hepatology1998; 28: 510–513.
5.
LingR., MutimerD., AhmedM., BoxallE.H., EliasE., DusheikoG.M., & HarrisonT.J.Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology1996; 24: 711–713.
6.
NaoumovN.V., ChokshiS., SmithH.M., & WilliamsR.Emergence and characterisation of lamivudine-resistant hepatitis B virus variant. Hepatology1996; 24: 282A.
7.
TipplesG.A., MaM.M., FischerK.P., BainV.G., KnetmanN.M., & TyrrellD.L.Mutation of HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.Hepatology1996; 24: 714–717.
8.
AllenM.I., DeslauriersM., AndrewsC.W., TipplesG.A., WaltersK.A., TyrrellD.L., BrownN., & CondreayL.D.Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology1998; 27: 1670–1677.
9.
AyeT.T., BartholomeuszA., ShawT., BowdenS., BreschkinA., McMillanJ., AngusP., & LocarniniS.Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. Journal of Hepatology1997; 26: 1148–1153.
10.
BartholomeuszA., & LocarniniS.Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. International Antiviral News1997; 5: 123–124.
11.
TillmannH.L., TrautweinC., KrugerM., BokerK., SchlittH.J., CondreayL.D., DeslauriersM., BrunsI., PichlmayrR., & MannsM.P.Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation. Journal of Hepatology1997; 26 (Suppl. 1):153.
12.
MelagariM., ScaglioniP.P., & WandsJ.R.Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology1998; 27: 628–633.
13.
BurroughsN.J., RandD.A., PillayD., EliasE., & MutimerD.The consequences of quasispecies heterogeneity and within-host ecology for antiviral therapy of hepatitis B virus. In Therapies for Viral Hepatitis1998; pp. 335–343. Edited by SchinaziR.F., SommadossiJ.P., & ThomasH.London: International Medical Press.
14.
ChayamaK., SuzukiY., KobayashiM., KobayashiM., TsubotaA., HashimotoM., MiyanoY., KoikeH., KobayashiM., KoidaI., AraseY., SaitohS., MurashimaN., IkedaK., & KumadaH.Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology1998; 27: 1711–1716.
15.
LocarniniS.A.Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology1998; 27: 294–297.
16.
SchuurmanR., NijhuisM., van LeeuwenR., SchipperP., de JongD., CollisP., DannerS.A., MulderJ., LovedayC., ChristophersonC., KwokS., SninskyJ., & BoucherC.A.B.Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases1995; 171: 1411–1419.
17.
SchinaziR.F., LloydR.M., NguyenM-H, CannonD.L., McMillanA., IlksoyN., ChuC.K., LiottaD.C., BazmiH.Z., & MellorsJ.W.Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy1993; 37: 875–881.
18.
BackN.K., NijhuisM., KeulenW., BoucherC.A., Oude EssinkB.O., van KuilenburgA.B., van GennipA.H., & BerkhoutB.Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO Journal1996; 15: 4040–4049.
19.
BoucherC.A., CammackN., SchipperP., SchuurmanR., RouseP., WainbergM.A., & CameronJ.M.High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy1993; 37: 2231–2234.
20.
LarderB.A., KempS.D., & HarriganP.R.Potential mechanism for sustained antiretroviral efficacy of AZT–3TC combination therapy. Science1995; 269: 696–699.
21.
TisdaleM., KempS.D., ParryN.R., & LarderB.A.Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA1993; 90: 5653–5656.
